Arcutis Biotherapeutics' CEO Frank Watanabe joins In Vivo’s David Wild to talk about building a patient‑first culture and turning a three‑person startup into a commercial‑stage immunodermatology company. He explains how Zoryve (roflumilast) is reshaping care in chronic inflammatory skin diseases, why Arcutis is pushing beyond dermatology offices into primary care and pediatrics, and how new assets like ARQ‑234 fit into the company’s long‑term growth strategy. The conversation also covers leadership lessons from Watanabe’s time in the US Navy Reserves, his practice of speaking directly with frontline employees and his perspective on capital markets and policy decisions that will shape the future of dermatology innovation.